CTLA4 and metastatic melanoma: Original indications were approved in metastatic melanoma, leading to unprecedented long-term survival outcomes with 5-year overall survival (OS) rates exceeding 50% with combination ipilimumab-nivolumab (anti-CTLA-4 and anti-PD-1) (4).